Company profile: Kronos Bio
1.1 - Company Overview
Company description
- Provider of oncology therapies that modulate historically undruggable cancer targets. Pipeline includes KB-0742, a CDK9 inhibitor in phase 1/2 for MYC-dependent tumors, and KB-9558 targeting the p300 KAT domain for multiple myeloma. Offers a Small Molecule Microarray screening platform for transcription factor binding assays and a discovery collaboration with Genentech.
Products and services
- Small Molecule Microarray (SMM) Screening Platform: Architects high-throughput binding assays against transcription factors in tumor cell lysate, maintaining endogenous protein structures to enable native-state target evaluation
- KB-0742: Engineers a clinical-stage CDK9 inhibitor in phase 1/2 to treat MYC-dependent tumors including triple-negative breast, non-small cell lung, ovarian, and other cancers
- KB-9558: Develops a domain-selective inhibitor targeting the KAT domain of p300 to modulate the IRF4 transcription regulatory network in multiple myeloma
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Kronos Bio
EOS
HQ: Italy
Website
- Description: Provider of biopharmaceutical research and development focused on creating novel medicines for the treatment of cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full EOS company profile →
NovaScan
HQ: United States
Website
- Description: Provider of cancer detection and surgical decision-support technologies based on Cole frequency measurements, including MarginScan for tissue-sparing skin cancer excisions with margin confirmation without histology; nsCanary for real-time biopsy assessment (pancreatic, biliary, lung); Predictive Technology to assess presence, aggressiveness, and metastasis likelihood; and an Electrical Mammogram detecting breast cancer without radiation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NovaScan company profile →
Viome Life Sciences
HQ: United States
Website
- Description: Provider of scientific discovery, research, and development services for health and chronic disease, offering RNA-based consumer analyses for health insights and precision nutrition, and advancing prediction, precision diagnostics, and therapeutics for chronic diseases, cancer, and aging, with RNA sequencing tests including gut microbiome, human gene expression, saliva, and vaginal.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Viome Life Sciences company profile →
Kiyatec
HQ: United States
Website
- Description: Provider of ex vivo 3D cell culture technology that uses a patient's own living tumor cells to create functional microtumor models for testing cancer therapies and predicting response. Offers 3D Predict Glioma and 3D Predict Oncology, patient-specific microtumor creation (up to 1,000) for drug testing, and a HIPAA-compliant portal delivering patient-specific reports within 7-10 days to aid treatment decisions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kiyatec company profile →
Barinthus Bio
HQ: United Kingdom
Website
- Description: Provider of clinical-stage immunotherapeutics and vaccines for infectious diseases and cancer, leveraging proprietary ChAdOx1/ChAdOx2 adenoviral vectors and MVA platforms to prime disease-specific T cells. Pipeline includes VTP-300 for chronic Hepatitis B, VTP-850 for prostate cancer, VTP-1000 for celiac disease, and the SNAP-TI platform to promote immune tolerance.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Barinthus Bio company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Kronos Bio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Kronos Bio
2.2 - Growth funds investing in similar companies to Kronos Bio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Kronos Bio
4.2 - Public trading comparable groups for Kronos Bio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →